Doxycycline for Lateral Epicondylalgia - RCT
|ClinicalTrials.gov Identifier: NCT00631501|
Recruitment Status : Unknown
Verified February 2008 by Kaunas University of Medicine.
Recruitment status was: Recruiting
First Posted : March 7, 2008
Last Update Posted : March 7, 2008
Matrix metalloproteinases are involved in the pathogenesis of tendinopathy. Doxycycline, a widely available pharmaceutical agent mostly used for its antibiotic properties, also functions as an inhibitor of MMPs.
This study aims to investigate the effect of doxycycline treatment on lateral epicondylalgia (tennis elbow). During three weeks, patients receive doxycycline tablets 100 mg twice daily, or placebo. Main outcome variable is pain (VAS) at three weeks.
Serum and/or plasma levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases are measured.
|Condition or disease||Intervention/treatment|
|Lateral Epicondylalgia (Tennis Elbow)||Drug: Placebo Drug: Doxycycline|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||34 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Placebo Comparator: 2||Drug: Placebo|
100 mg twice daily
- Pain (VAS)
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00631501
|Contact: Alfredas Smailys, MD, PhD||+370 37 email@example.com|
|Dept of Orthopaedics, Kaunas Medical University||Recruiting|
|Contact: Alfredas Smailys firstname.lastname@example.org|